MDS Pharma Revenues Continue to Fall, Hunt for Buyer Continues

Friday, September 11, 2009 06:42 AM

Revenues continue to fall at MDS Pharma, the contract research arm of Toronto-based MDS. Third-quarter 2009 net revenues fell 28% from the same period last year, dropping to $49 million from $68 million. The year-over-year decline was a result of decreased demand for phase I and bioanalytical services, the company said.

Adjusted EBITDA for the contract research organization (CRO) was a loss of $14 million. In an effort to save $9 million annually, MDS initiated restructuring activities in the third quarter, laying off approximately 200 employees

Earlier this month, MDS announced plans to sell its entire CRO business—just two months after selling its late-stage operations and announcing it was reorganizing to focus on early-stage drug development. If a suitable buyer is not found, MDS said it will retain the early-stage division and invest in building the business.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs